May 05, 2016
Expanding Our Cystic Fibrosis Collaboration with Galapagos
The cystic fibrosis (CF) combination therapy we are developing with Galapagos is on track. Following successful completion of Phase 2 development, AbbVie will be responsible for Phase 3.

With a potential breakthrough triple combination therapy for cystic fibrosis (CF) in development, AbbVie and Galapagos are aspiring to address 90 percent of patients with cystic fibrosis. Upon successful completion by Galapagos of clinical development through to completion of Phase 2, AbbVie will be responsible for Phase 3 development.
CF is a rare, life-threatening, genetic disease that affects approximately 80,000 patients worldwide. It is a chronic disease that affects the lungs and digestive system. CF patients, with significantly impaired quality of life, have an average lifespan approximately 50 percent shorter than the population average, with the median age of death at 40. There currently is no cure for CF.
Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.

Learn more by reading the Galapagos press release.



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?